Today, Novo Nordisk estimates that just under 20 million people are treated with GLP-1 drugs.4 Given a well-stocked pipeline, a substantial global addressable population (the obese population alone is projected to exceed 1.2 billion by 20305), and in light of the very beneficial clinical profile of these drugs, it is plausible that over 100 million patients worldwide will be treated with GLP-1s in the near future
Metabolic syndrome in the rat: Females are protected against the pro-oxidant effect of a high sucrose diet
However, if youre vegan, vegetarian, or have absorption issues, food alone may not be enough
For example, paclitaxel can alter the integrity of the bloodbrain barrier, potentially allowing harmful substances to enter the brain and contributing to neurotoxicity (Patai et al., 2025)
Both outcomes are valid
Again there is a potential to eat through all of this, just like anything else